GlassScriptPhysician profile
Marissa Torres
NPI 1285199794
$11,709.12
in general payments reported to CMS, 2019-2025
66 companies · $2,779 in 2025
The $2,779 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,019 · 2022: $1,590 · 2023: $2,555 · 2024: $2,766 · 2025: $2,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,100.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,901.18 | 2021-2025 | |
| Ucb, INC. | $791.98 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $584.74 | 2021-2025 | Vumerity, Tysabri, Plegridy |
| Neurelis, INC. | $467.42 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $405.83 | 2022-2025 | |
| Lilly USA, LLC | $398.49 | 2021-2025 | Emgality, Kisunla, Amyvid |
| Pfizer INC. | $374.60 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $351.58 | 2021-2025 | Ingrezza, Ongentys |
| Axsome Therapeutics, INC. | $322.08 | 2023-2025 | Sunosi, Auvelity, Symbravo |
| Alnylam Pharmaceuticals INC. | $319.86 | 2021-2025 | Onpattro, Amvuttra |
| Mdd US Operations, LLC | $319.02 | 2023-2025 | Gocovri, Gocovri |
| Lundbeck LLC | $307.45 | 2022-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $301.52 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $264.67 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biohaven Pharmaceuticals, INC. | $241.46 | 2021 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.